Kimberly Forcinel, APRN
Psychiatric/Mental Health · Shreveport, LANPI 1124406400
Payments from drug & device makers
Across 760 payments — averaging $120.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$63K
- Neurocrine Biosciences, Inc.$19K
- AbbVie$2K
- Alkermes, Inc.$2K
- Otsuka America Pharmaceutical, Inc.$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$958
- plus $4K from 19 others
What the payments were for
- Consulting fees$9,43810%
- Speaking & faculty fees$60,09366%
- Travel & lodging$4,7175%
- Food & beverage$16,99119%
- Education$3700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 190 | $62,788 |
| Neurocrine Biosciences, Inc. | 124 | $19,192 |
| AbbVie | 129 | $2,022 |
| Alkermes, Inc. | 90 | $1,589 |
| Otsuka America Pharmaceutical, Inc. | 38 | $1,115 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 48 | $958 |
| Johnson & Johnson | 40 | $857 |
| E.r. Squibb & Sons, L.L.C. | 28 | $401 |
| Axsome Therapeutics, Inc. | 3 | $326 |
| Sunovion Pharmaceuticals Inc. | 24 | $277 |
| Abbott | 2 | $261 |
| Indivior Inc. | 17 | $231 |
| Vanda Pharmaceuticals Inc. | 8 | $228 |
| Tris Pharma Inc | 1 | $152 |
| Lundbeck LLC | 8 | $131 |
| Insulet Corporation | 1 | $127 |
| Neurelis, Inc. | 1 | $125 |
| Ardelyx, Inc. | 1 | $125 |
| Phathom Pharmaceuticals, Inc. | 1 | $125 |
| AstraZeneca | 1 | $125 |
| Sage Therapeutics, LLC | 1 | $120 |
| Gilead | 1 | $120 |
| GSK | 1 | $113 |
| Medtronic | 1 | $57 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $44 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UZEDY$44,748
- INGREZZA$17,088
- Austedo XR$15,102
- LYBALVI$1,479
- VRAYLAR$1,244
- ARISTADA$944
- AUSTEDO$385
- REXULTI$375
- INVEGA SUSTENNA$354
- FREESTYLE LIBRE 3$261
- CAPLYTA$250
- ABILIFY MAINTENA$245
- Auvelity$241
- ARISTADA INITIO$236
- Dyanavel XR$152
- COBENFY$135
- Omnipod$127
- ONGENTYS$125
- ULTOMIRIS$125
- VOQUEZNA$125
How this compares
$91,608 in reported general payments places this provider in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Invega SustennaPaliperidone Palmitate | 118 | $385,686 |
| IngrezzaValbenazine Tosylate | 14 | $119,378 |
| AristadaAripiprazole Lauroxil | 23 | $79,284 |
| UzedyRisperidone | 15 | $72,737 |
| VraylarCariprazine Hcl | 28 | $40,473 |
| RexultiBrexpiprazole | 13 | $19,066 |
| Fluphenazine Hcl | 58 | $18,019 |
| Fluphenazine Decanoate | 18 | $4,249 |
| Divalproex Sodium ErDivalproex Sodium | 75 | $3,819 |
| Oxcarbazepine | 51 | $2,199 |
| Duloxetine Hcl | 55 | $1,816 |
| Lurasidone Hcl | 18 | $1,461 |
| Trazodone Hcl | 80 | $1,388 |
| Divalproex Sodium | 59 | $1,351 |
| Aripiprazole | 47 | $1,200 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Sustenna | $857 | $385,686118 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $19,192 | $119,37814 claims |
| Alkermes, Inc.Aristada | $1,589 | $79,28423 claims |
| Teva Pharmaceuticals USA, Inc.Uzedy | $62,788 | $72,73715 claims |
| AbbVieVraylar | $2,022 | $40,47328 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,115 | $19,06613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 615 psychiatric/mental health providers in Louisiana.
Other psychiatric/mental health in Shreveport
- Zachary FussellShreveport$9K
- Lisa BakerShreveport$9K
- Jaschandria BellShreveport$8K
- Shannon JacksonShreveport$8K
- Amy LacoutureBaton Rouge$663K
- Amanda EymardHouma$617K
- Amber LittlefieldBroussard$225K
- Timothy PellegrinHouma$210K
- Melissa GuilbeauLafayette$122K
- Sattaria DilksLake Charles$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.